Clinical, biologic, and immunologic characteristics of the 124 MZL patients according to the morphologic variants
| . | SLVL . | Common . | Large Cell-Rich . | P Value . |
|---|---|---|---|---|
| Age >60 y | 11 (92%) | 42 (54%) | 14 (41%) | .01 |
| Performance status ≥2 | — | 14 (20%) | 7 (22%) | |
| Peripheral lymph nodes | 1 (8%) | 30 (38.5%) | 24 (71%) | .0002 |
| Profound lymph nodes | — | 35 (45%) | 14 (41%) | .01 |
| Large spleen | 12 (100%) | 52 (67%) | 15 (44%) | .002 |
| Localized stage | 1 (8%) | 9 (11.5%) | 8 (23.5%) | |
| Bone marrow infiltration | 10 (83%) | 63 (81%) | 17 (50%) | .002 |
| High LDH | 3 (30%) | 26 (42%) | 14 (50%) | |
| High β2-microglobulin | 8 (89%) | 36 (64%) | 8 (35%) | <.01 |
| Blood infiltration | 10 (83%) | 39 (51%) | 4 (12%) | <.0001 |
| High/intermediate-high risk IPI | 4 (40%) | 34 (57%) | 13 (46%) |
| . | SLVL . | Common . | Large Cell-Rich . | P Value . |
|---|---|---|---|---|
| Age >60 y | 11 (92%) | 42 (54%) | 14 (41%) | .01 |
| Performance status ≥2 | — | 14 (20%) | 7 (22%) | |
| Peripheral lymph nodes | 1 (8%) | 30 (38.5%) | 24 (71%) | .0002 |
| Profound lymph nodes | — | 35 (45%) | 14 (41%) | .01 |
| Large spleen | 12 (100%) | 52 (67%) | 15 (44%) | .002 |
| Localized stage | 1 (8%) | 9 (11.5%) | 8 (23.5%) | |
| Bone marrow infiltration | 10 (83%) | 63 (81%) | 17 (50%) | .002 |
| High LDH | 3 (30%) | 26 (42%) | 14 (50%) | |
| High β2-microglobulin | 8 (89%) | 36 (64%) | 8 (35%) | <.01 |
| Blood infiltration | 10 (83%) | 39 (51%) | 4 (12%) | <.0001 |
| High/intermediate-high risk IPI | 4 (40%) | 34 (57%) | 13 (46%) |
IPI = International Prognostic Index; LDH = lactic dehydrogenase; MZL = marginal zone B-cell lymphoma; SLVL = splenic lymphoma with villous lymphocyte.